Hao Chi Zhang, MD
Department of Gastroenterology & Hepatology, Division of Internal Medicine
Present Title & Affiliation
Primary Appointment
Associate Professor, Gastroenterology & Hepatology, Internal Medicine, UT MD Anderson Cancer Center, Houston, TX
Education & Training
Degree-Granting Education
| 2013 | UT Southwestern Medical School, Dallas, Texas, US, Medicine, MD |
| 2008 | Stanford University, Stanford, California, US, Biological Sciences, BS |
Postgraduate Training
| 2016-2019 | Clinical Fellowship, Internal Medicine, UT Health Science Center at Houston - McGovern at UTHealth Houston, Houston, TX |
| 2013-2016 | Clinical Residency, Internal Medicine, Baylor College of Medicine, Houston, Texas |
Licenses & Certifications
| 2019 | Texas Medical Board |
| 2019 | American Board of Internal Medicine Gastroenterology |
| 2016 | American Board of Internal Medicine |
Experience & Service
Faculty Academic Appointments
Assistant Professor, Gastroenterology, Hepatology & Nutrition, Internal Medicine, UT MD Anderson Cancer Center, Houston, TX, 2019 - 2026
Administrative Appointments/Responsibilities
Program Director, Gastroenterology & Hepatology, The University of Texas MD Anderson Cancer Center, Houston, TX, 2025 - Present
Interim Program Director, Gastroenterology, Hepatology & Nutrition, The University of Texas MD Anderson Cancer Center, Houston, TX, 2025
Associate Program Director, Gastroenterology, Hepatology & Nutrition, The University of Texas MD Anderson Cancer Center, Houston, TX, 2023 - 2025
Co-Director of the MDA GHN/Pathology Departmental Conferences, Gastroenterology, Hepatology & Nutrition, The University of Texas MD Anderson Cancer Center, Houston, TX, 2023 - Present
Chief Clinical Fellow, Internal Medicine, UT Health Science Center at Houston, Houston, TX, 2018 - 2019
Intramural Institutional Committee Activities
Member, MDA IOTOX Clinical Committee, The University of Texas MD Anderson Cancer Center, 2025 - Present
Extramural Institutional Committee Activities
Member, DoIM Immuno-Oncology (IO) Toxicity Group, The University of Texas MD Anderson Cancer Center, 2020 - Present
Member of the Education Portfolio Sub-committee, DoIM Education Committee – Education Group, The University of Texas MD Anderson Cancer Center, 2020 - Present
Member, GHN Fellowship Development Group, The University of Texas MD Anderson Cancer Center, 2020 - Present
Honors & Awards
| 2026 | Nomination for Excellence in Education, UT MD Anderson Cancer Center |
| 2023 | Nomination for Excellence in Education, UT MD Anderson Cancer Center |
| 2017 | Certificate for Outstanding Clinical Fellow: Patient Care, MD Anderson Cancer Center: Division of Gastroenterology, Hepatology and Nutrition |
| 2016 | Academy of Residency Educators Certificate, Baylor College of Medicine |
| 2016 | Award for Resident Morning Report of the Month, Baylor St. Luke's Medical Center |
Professional Memberships
Selected Presentations & Talks
Local Presentations
- 2026. Treatment of Refractory Immune Checkpoint Inhibitor-Mediated Hepatobiliary Toxicity with IL-2R-alpha Blockage/Anti-CD25. Invited. ASPirE - Clinical Cases of Immunotherapy Toxicity. Houston, TX, US.
- 2025. Immune-Mediated Hepatobiliary Toxicity: Shaping Paradigms. Invited. UT MDACC Gastroenterology & Hepatology - Onco-Gastroenterology Conference. Houston, TX, US.
- 2024. A Case of Successful Treatment of High-Grade Immune-Mediated Hepatobiliary Toxicity with Oral Budesonide: Shifting the Paradigm Away From Systemic Steroids. Poster. Treating Immune-Related Adverse Events: Integrating Insights from Clinical, Translational and Basic Science. Houston, TX, US.
- 2024. Steatotic Liver Disease: From Basics to Experiences at a Cancer Center. Invited. Greater Houston Society of Gastroenterology Nurses and Associates (SGNA) 2024 Annual Conference. Houston, Texas, US.
- 2023. The Evolving Landscape in Immune-Mediated Hepatobiliary Toxicity: Refining the Paradigms. Invited. UT MDACC Department of Melanoma Medical Oncology Grand Rounds. Houston, TX, US.
- 2023. Management of Patients with Portal Hypertension at a Cancer Center. Invited. Greater Houston Society of Gastroenterology Nurses & Associates (SGNA) Virtual. Houston, Texas, US.
- 2022. The Evolving Landscape of Immune-Mediated Hepatobiliary Toxicity: The MD Anderson Experience. Invited. McGovern Medical School at UTHealth GHN Grand Rounds. Houston, TX, US.
- 2021. The Evolving Landscape of Immune-Mediated Hepatobiliary Toxicity. Invited. McGovern Medical School at UTHealth GHN Grand Rounds. Houston, TX, US.
- 2020. Becoming the Lifeguard for the Decompensated Cirrhotic with Ascites. Invited. UT MDACC Division of Internal Medicine Grand Rounds. Houston, TX, US.
- 2020. Current Landscape in Immune Checkpoint Inhibitor-Mediated Hepatobiliary Toxicity. Invited. McGovern Medical School at UTHealth GHN Grand Rounds. Houston, TX, US.
Regional Presentations
- 2026. Immune Checkpoint Inhibitor-Induced Liver Injury: An Evolving Practical Approach. Invited. UT MD Anderson Cancer Center - Summer Sawyer GI Conference 2026. San Antonio, TX, US.
National Presentations
- 2025. A Strategy Utilizing Tocilizumab, Budesonide, and Mycophenolate Mofetil in the Peri-Operative Period to Achieve Biochemical Remission in High-Grade Immune Checkpoint Inhibitor-Mediated Cholangiohepatitis: A Case Study. Poster. American College of Gastroenterology (ACG) 2025 - Annual Scientific Meeting & Postgraduate Course. Phoenix, AZ, US.
- 2025. Successful Management With Oral Budesonide to Treat Pan-Upper Gastrointestinal Toxicity Secondary to Immune Checkpoint Inhibitor Therapy. Poster. American College of Gastroenterology (ACG) 2025 - Annual Scientific Meeting & Postgraduate Course. Phoenix, AZ, US.
- 2025. Oral Budesonide for the Treatment of Immune Checkpoint Inhibitor-Mediated Hepatobiliary Toxicities: A Case Series. Poster. Digestive Disease Week (DDW) 2025. San Diego, CA, US.
- 2025. Oral Budesonide for the Treatment of Immune Checkpoint Inhibitor-Mediated Hepatobiliary Toxicities: A Case Series. Poster. Duke NICT 2025 and ASPirE 2025. Cary, North Carolina, US.
- 2024. A Case of Successful Treatment of High-Grade Immune-Mediated Hepatobiliary Toxicity With Oral Budesonide: Shifting the Paradigm Away From Systemic Steroids. Poster. American College of Gastroenterology (ACG) 2024 - Annual Scientific Meeting & Postgraduate Course. Philadelphia, PA, US.
- 2024. Utilization of Scheduled Simulator Based Endoscopy Training Enables Sustained Improvement of Key Endoscopic Skills. Poster. American College of Gastroenterology (ACG) 2024 - Annual Scientific Meeting & Postgraduate Course. Philadelphia, PA, US.
- 2024. Immune-Mediated Hepatobiliary Toxicity: The Journey Towards Biochemical Remission. Invited. Management of Checkpoint Inhibitor-Related Toxicity. Cleveland, OH, US.
- 2023. Immune-Mediated Hepatobiliary Toxicity: The Journey Towards Biochemical Remission. Invited. IOTOX Clinical Education Symposium. Houston, TX, US.
- 2023. Gastrointestinal Adverse Events Following Brentuximab Vedotin and Polatuzumab Vedotin Therapy. Poster. American College of Gastroenterology (ACG) 2023 - Annual Scientific Meeting & Postgraduate Course. Vancouver, CA.
- 2023. Similar Features of PET Scan in Gastrointestinal Tract Related to Metformin and Immune Related Enterocolitis. Poster. American College of Gastroenterology (ACG) 2023 - Annual Scientific Meeting & Postgraduate Course. Vancouver, CA.
- 2023. Effect of PD-1/ PD-L1 and Statin Combination Therapy on Gastrointestinal Toxicity Related to Immune Checkpoint Inhibitors and on Survival. Poster. American College of Gastroenterology (ACG) 2023 - Annual Scientific Meeting & Postgraduate Course. Vancouver, CA.
- 2023. Implementation of an Enhanced "Step-Up" Approach Towards Early Tocilizumab for Management of Immune Checkpoint Inhibitor-Mediated Hepatotoxicity: A Case Study in Revisiting Paradigms of Treatment. Poster. American College of Gastroenterology (ACG) 2023 - Annual Scientific Meeting & Postgraduate Course. Vancouver, CA.
- 2023. The Interplay Between Immunocompromise and Immunotherapy Affects the Risk of Inflammatory Adverse Events. Poster. American College of Gastroenterology (ACG) 2023 - Annual Scientific Meeting & Postgraduate Course. Vancouver, CA.
- 2023. Mogamulizumab-Induced Cholangiopathy in a Patient With Cutaneous T-Cell Lymphoma: A Case Study. Poster. American College of Gastroenterology (ACG) 2023 - Annual Scientific Meeting & Postgraduate Course. Vancouver, CA.
- 2023. Early Tocilizumab as a Rescue Therapy for Steroid-Dependent Immune Checkpoint Inhibitor-Mediated Hepatotoxicity: A Case for Decoupling Steroid Dependency. Poster. American College of Gastroenterology (ACG) 2023 - Annual Scientific Meeting & Postgraduate Course. Vancouver, CA.
- 2023. Immune-Mediated Cholangiopathic Toxicity: A Case of Immunotherapy-Related Sclerosing Cholangitis. Poster. American College of Gastroenterology (ACG) 2023 - Annual Scientific Meeting & Postgraduate Course. Vancouver, CA.
- 2023. A Rare Case of HBV Reactivation With Delayed Cholestatic Effect Secondary to Acalabrutinib. Poster. American College of Gastroenterology (ACG) 2023 - Annual Scientific Meeting & Postgraduate Course. Vancouver, CA.
- 2023. The Evolving Landscape in Immune-Mediated Hepatobiliary Toxicity: Advancing the Field. Invited. Advances in Cancer Immunotherapy - A Focus on Toxicity Management. Houston, TX, US.
- 2023. The Evolving Landscape in Immune-Mediated Hepatobiliary Toxicity: Advancing the Field. Invited. Project ECHO: Tele-monitoring to Manage Immune-related Adverse Events in Patients Receiving Cancer Immunotherapies. Houston, TX, US.
- 2022. The Evolving Landscape in Immune-Mediated Hepatobiliary Toxicity: Advancing the Field. Invited. IOTOX Clinical Education Symposium. Houston, TX, US.
- 2022. Characteristics, Treatment and Outcome of Patients With Bowel Perforation After Immune Checkpoint Inhibitor Exposure. Poster. American College of Gastroenterology (ACG) 2022 - Annual Scientific Meeting & Postgraduate Course. Charlotte, NC, US.
- 2022. Characteristics, Treatment and Outcome of Patients With Previously Diagnosed Autoimmune Disease After Immune Checkpoint Inhibitor Exposure. Poster. American College of Gastroenterology (ACG) 2022 - Annual Scientific Meeting & Postgraduate Course. Charlotte, NC, US.
- 2022. Statin-Related Autoimmune Hepatitis: A Case Study of a Rare Entity and Review of Current Knowledge. Poster. American College of Gastroenterology (ACG) 2022 - Annual Scientific Meeting & Postgraduate Course. Charlotte, NC, US.
- 2022. Metastatic Merkel Cell Carcinoma Presenting as Silent Infiltrative Liver Disease: A Lesson Emphasizing the Utility of Liver Biopsy in the Exclusion of Immune Checkpoint Inhibitor-Mediated Hepatotoxicity. Poster. American College of Gastroenterology (ACG) 2022 - Annual Scientific Meeting & Postgraduate Course. Charlotte, NC, US.
- 2022. Characteristics of Appendicitis After Immune Checkpoint Inhibitors Among Cancer Patients. Poster. American College of Gastroenterology (ACG) 2022 - Annual Scientific Meeting & Postgraduate Course. Charlotte, NC, US.
- 2022. Tocilizumab as an Effective Steroid-Sparing Agent for the Treatment of Recurrent and Steroid-Dependent Immune Checkpoint Inhibitor-Mediated Hepatotoxicity: A Case Study and Insight into Pathophysiology. Poster. American College of Gastroenterology (ACG) 2022 - Annual Scientific Meeting & Postgraduate Course. Charlotte, NC, US.
- 2022. Early Use of Tocilizumab as an Effective Steroid-Sparing Strategy for the Treatment of Immune Checkpoint Inhibitor-Mediated Cholangiopathy: Building Foundations for Personalized Management. Poster. American College of Gastroenterology (ACG) 2022 - Annual Scientific Meeting & Postgraduate Course. Charlotte, NC, US.
- 2022. Vanishing Bile Duct Syndrome in the Setting of Newly Diagnosed Hodgkin Lymphoma. Poster. American College of Gastroenterology (ACG) 2022 - Annual Scientific Meeting & Postgraduate Course. Charlotte, NC, US.
- 2022. C-Reactive Protein Is Not a Reliable Biomarker to Assess the Severity and Response of Immune-Mediated Diarrhea and Colitis. Poster. American College of Gastroenterology (ACG) 2022 - Annual Scientific Meeting & Postgraduate Course. Charlotte, NC, US.
- 2022. Characteristics, Treatment and Outcome of Patients With Previously Diagnosed Autoimmune Disease After Immune Checkpoint Inhibitor Exposure. Poster. American College of Gastroenterology (ACG) 2022 - Annual Scientific Meeting & Postgraduate Course. Charlotte, NC, US.
- 2021. Tocilizumab as an alternative treatment strategy for immunotherapy-mediated hepatobiliary toxicity: addressing an urgent unmet need. Poster. American Association for the Study of Liver Diseases (AASLD) 2021 - The Liver Meeting - Virtual, US.
- 2021. Budesonide as an Alternative Steroid Agent, in Combination With Adjunctive Agents, for the Treatment of Immune Checkpoint Inhibitor-Mediated Cholangiohepatitis: A Case Study. Poster. American College of Gastroenterology (ACG) 2021 - Annual Scientific Meeting & Postgraduate Course. Las Vegas, Nevada, US.
- 2021. Severe Cholestasis as a Paraneoplastic Phenomenon Associated With Adrenocortical Carcinoma. Poster. American College of Gastroenterology (ACG) 2021 - Annual Scientific Meeting & Postgraduate Course. Las Vegas, Nevada, US.
- 2021. Clinical Presentation, Treatment Strategies, and Chronic Sequelae of Immune Checkpoint Inhibitor-Mediated Cholangiopathy: A Case Study. Poster. American College of Gastroenterology (ACG) 2021 - Annual Scientific Meeting & Postgraduate Course. Las Vegas, Nevada, US.
- 2021. Extrahepatic Biliary Sequelae in Immune Checkpoint Inhibitor-Mediated Cholangiohepatitis: Urgent Unmet Need for Early Effective Treatment. ACG 2021 Annual Scientific Meeting Abstracts. Poster. American College of Gastroenterology (ACG) 2021 - Annual Scientific Meeting & Postgraduate Course. Las Vegas, Nevada, US.
- 2021. DIAGNOSIS AND CHARACTERISTICS OF IMMUNE CHECKPOINT INHIBITOR-MEDIATED CHOLANGIOPATHY: A CASE SERIES. Poster. Digestive Disease Week (DDW) 2021 - Virtual, US.
- 2021. Moderate dose steroid treatment for immune checkpoint inhibitor-mediated hepatotoxicity. Invited. Digestive Disease Week (DDW) 2021 - Virtual, US.
- 2021. Fecal calprotectin concentration to assess endoscopic and histologic remission in patients with immune-mediated diarrhea and colitis. Poster. Digestive Disease Week (DDW) 2021 - Virtual, US.
- 2020. Safety of Immune Checkpoint Inhibitors in Cancer Patients with Chronic Hepatitis C Infection: A Prospective Observational Study. Poster. American Association for the Study of Liver Diseases (AASLD) 2021 - The Liver Meeting - Virtual, US.
- 2020. Education of Trainees and Endoscopy Technicians in Electrosurgical Unit Operations in the Endoscopy Unit. Poster. American College of Gastroenterology (ACG) 2020 - Annual Scientific Meeting & Postgraduate Course - Virtual, US.
- 2019. Isolated Polycystic Liver Disease: Case of Long-Term Progression of Hepatic Cyst. Poster. American College of Gastroenterology (ACG) 2019 - Annual Scientific Meeting & Postgraduate Course. San Antonio, TX, US.
- 2018. Acute liver injury in the context of immune checkpoint inhibitor-related colitis treated with infliximab. Poster. Society for Immunotherapy of Cancer (SITC) 2018 - 33rd Annual Meeting. Washington, D.C, US.
- 2018. Development of Cirrhosis and Portal Hypertension in Fontan-Associated Liver Disease. Poster. American College of Gastroenterology (ACG) 2018 - Annual Scientific Meeting & Postgraduate Course. Philadelphia, PA, US.
- 2018. Management of Refractory Bleeding from Peristomal Varices Secondary to Oxaliplatin-Associated Portal Hypertension. Poster. American College of Gastroenterology (ACG) 2018 - Annual Scientific Meeting & Postgraduate Course. Philadelphia, PA, US.
- 2018. Identification and Surveillance of Multiple Hepatic Adenomas in Glycogen Storage Disease Type Ia. Poster. American College of Gastroenterology (ACG) 2018 - Annual Scientific Meeting & Postgraduate Course. Philadelphia, PA, US.
- 2018. Persistent Hepatitis A IgM Antibody: A Clue in the Diagnosis of Autoimmune Hepatitis. Poster. American College of Gastroenterology (ACG) 2018 - Annual Scientific Meeting & Postgraduate Course. Philadelphia, PA, US.
- 2017. Esophageal Squamous Papillomatosis in a Patient With Dermatologic Lesions. Poster. American College of Gastroenterology (ACG) 2017 - World Congress of Gastroenterology. Orlando, FL, US.
- 2017. Adverse Hepatobiliary Effects of Pegaspargase: Diagnostic Features and Potential Treatment. Poster. American College of Gastroenterology (ACG) 2017 - World Congress of Gastroenterology. Orlando, FL, US.
- 2017. Analyzing Abnormal Liver Enzymes in a Patient With Renal Cell Carcinoma. Poster. American College of Gastroenterology (ACG) 2017 - World Congress of Gastroenterology. Orlando, FL, US.
- 2017. Immune-Related Pancreatitis Secondary to Ipilimumab and Nivolumab in a Patient With Melanoma. Poster. American College of Gastroenterology (ACG) 2017 - World Congress of Gastroenterology. Orlando, FL, US.
- 2017. Challenges in Management of Gastrointestinal Bleeding in Blue Rubber Bleb Nevus Syndrome. Poster. American College of Gastroenterology (ACG) 2017 - World Congress of Gastroenterology. Orlando, FL, US.
- 2017. Gastrointestinal Bleeding From Metastatic Angiosarcoma Identified in the Gastrointestinal Tract. Poster. American College of Gastroenterology (ACG) 2017 - World Congress of Gastroenterology. Orlando, FL, US.
- 2016. Presence of Colonic Dysplasia prior to Colorectal Cancer Diagnosis is Associated with Early Stage Cancer among Patients with Inflammatory Bowel Disease: A National Cohort Study. Poster. Digestive Disease Week (DDW) 2016. San Diego, CA, US.
- 2016. Colorectal Cancer is Diagnosed Earlier after Inflammatory Bowel Disease Diagnosis in African-Americans Compared to Whites in a VA Population. Poster. Digestive Disease Week (DDW) 2016. San Diego, CA, US.
- 2015. A Case of Pancreaticobiliary Adenocarcinoma Secondary to Malignant Transformation of Remnant Tissue from a Type I Choledochal Cyst. Poster. American College of Gastroenterology (ACG) 2015 - Annual Scientific Meeting. Honolulu, HI, US.
- 2015. A Rare Cause of Abnormal Liver Enzymes in an HIV-Infected Patient. Poster. American College of Gastroenterology (ACG) 2015 - Annual Scientific Meeting. Honolulu, HI, US.
- 2015. Refractory Gastrointestinal Bleeding from Portal Hypertensive Gastropathy. Poster. American College of Gastroenterology (ACG) 2015 - Annual Scientific Meeting. Honolulu, HI, US.
International Presentations
- 2022. Current Landscape in Immune Checkpoint Inhibitor-Mediated Hepatobiliary Toxicity. Invited. Department of Pharmacy - Beijing Chaoyang Hospital, Capital Medical University (Virtual). Beijing, CN.
Formal Peers
- 2026. Cholestatic Liver Diseases: A Focus on Primary Biliary Cholangitis & Primary Sclerosing Cholangitis. Galveston, TX, US.
- 2026. Interpretation of Liver Biochemistries: A Practical Approach. Houston, TX, US.
- 2026. Portal Hypertension & Cirrhosis: A Practical Guide for Practice in a Cancer Hospital. Houston, TX, US.
- 2026. Autoimmune hepatitis, primary biliary cholangitis, primary sclerosing cholangitis. Houston, TX, US.
- 2026. What the General Internist Needs to Know about Hepatocellular Carcinoma. Galveston, TX, US.
- 2026. A Review of the Basics of the Electrosurgical Unit (ESU) in Endoscopy for GI Fellows. Houston, Texas, US.
- 2025. Portal Hypertension & Cirrhosis: A Practical Guide for Practice in a Cancer Hospital. Houston, TX, US.
- 2025. GI Board Review: Pancreaticobiliary Topics. Houston, TX, US.
- 2025. Immune-Mediated Hepatobiliary Toxicity: An Update on Clinical Insights. Houston, TX, US.
- 2024. H. pylori Basics. Houston, TX, US.
- 2024. Portal Hypertension & Introduction to Cirrhosis: Part 2. Houston, TX, US.
- 2024. Peri-operative evaluation for patients with cirrhosis/portal hypertension. Houston, TX, US.
- 2024. What the General Internist Needs to Know About Hepatocellular Carcinoma. Galveston, TX, US.
- 2024. Colonic Polyp Management and ESU Basics. Houston, TX, US.
- 2024. Steatotic Liver Disease: From Basics to Experiences at a Cancer Center. Houston, TX, US.
- 2024. Portal Hypertension & Introduction to Cirrhosis: Part 1. Houston, TX, US.
- 2024. Immune-Mediated Hepatobiliary Toxicity: The Journey Towards Biochemical Remission. Houston, TX, US.
- 2024. Immune-Mediated Hepatobiliary Toxicity: The Journey Towards Biochemical Remission. Houston, TX, US.
- 2024. Immune-Mediated Hepatobiliary Toxicity: The Journey Towards Biochemical Remission. Houston, TX, US.
- 2024. Autoimmune hepatitis, primary biliary cholangitis, primary sclerosing cholangitis. Houston, TX, US.
- 2023. Management of Patients with Portal Hypertension at a Cancer Center. Visiting. Houston, TX, US.
- 2023. Portal Hypertension: Practical Management Tips for MD Anderson Cancer Hospital Medicine. Houston, TX, US.
- 2023. What the General Internist Needs to Know About Hepatocellular Carcinoma. Galveston, Texas, US.
- 2023. Portal Hypertension & Introduction to Cirrhosis: Part 2. Houston, TX, US.
- 2023. The Evolving Landscape in Immune-Mediated Hepatobiliary Toxicity: Refining the Paradigms. Visiting. Houston, TX, US.
- 2023. The Evolving Landscape in Immune-Mediated Hepatobiliary Toxicity: The MD Anderson Experience. Visiting. Houston, TX, US.
- 2023. Portal Hypertension & Introduction to Cirrhosis: Part 1. Houston, TX, US.
- 2022. The Evolving Landscape in Immune-Mediated Hepatobiliary Toxicity: Advancing the Field. Visiting. Houston, TX, US.
- 2022. Introduction to Liver Disease. Houston, TX, US.
- 2022. Early Use of Tocilizumab as an Effective Steroid-Sparing Strategy for the Treatment of Immune Checkpoint Inhibitor-Mediated Cholangiopathy: A Case Study. Visiting. Houston, TX, US.
- 2022. The Evolving Landscape of Immune-Mediated Hepatobiliary Toxicity. Visiting. Houston, TX, US.
- 2022. Case presentation. Visiting. Houston, TX, US.
- 2022. Paradigms in Management of Immune-Mediated Hepatobiliary Toxicities. Visiting. Houston, TX, US.
- 2022. Liver Disease: A Practical Crash Course. Galveston, Texas, US.
- 2022. Challenging Cases in Immune-Mediated Hepatobiliary Toxicity (IMH). Visiting. Houston, TX, US.
- 2021. The Evolving Landscape of Immune-Mediated Hepatobiliary Toxicity. Visiting. Houston, TX, US.
- 2020. Current Landscape in Immune-Mediated Hepatobiliary Toxicity. Visiting. Houston, TX, US.
- 2020. Becoming the Lifeguard for the Decompensated Cirrhotic with Ascites. Visiting. Houston, TX, US.
- 2020. Current Landscape in Immune-Mediated Hepatobiliary Toxicity. Visiting. Houston, TX, US.
- 2020. Nephrology 101 for the Gastroenterologist/Hepatologist. Visiting. Houston, TX, US.
- 2020. Case presentation. Visiting. Houston, TX, US.
- 2020. Case presentation. Visiting. Houston, TX, US.
- 2020. Hepatic Encephalopathy: A Practical Approach. Visiting. Houston, TX, US.
- 2019. Hepatic Encephalopathy: A Practical Approach. Houston, TX, US.
Selected Publications
Peer-Reviewed Articles
- Kuang AG, Shatila M, Shah JS, Mittal N, Naz S, Ebinama U, Iyer SP, Strati P, Shafi MA, Thomas AS, Zhang HC, Wang Y. Gastrointestinal adverse events following brentuximab vedotin and polatuzumab vedotin therapy. Ther Adv Med Oncol 18:17588359261417635, 2026. e-Pub 2026. PMID: 41705138.
- Shatila, M, Abdul-baki, K, Urias Rivera, AC, Takigawa, K, Lee, IA, Sullivan, A, Gupta, T, Lu, L, Menon, R, Khan, A, Salim, H, Baerman, E, Cruz, CC, Natha, C, Vemulapalli, V, Coleman, G, Varatharajalu, K, Fan, C, Okhuysen, PC, Olszanski, AJ, Zhou, Y, Zhang, HC, Shafi, MA, Wang, Y. Gastrointestinal Infection Before Immune Checkpoint Inhibition Hinders Treatment Efficacy and Increases the Risk of Colitis. Cancer medicine 14(15), 2025. e-Pub 2025. PMID: 40785196.
- Mazhuvanchery C, Indulkar S, Triadafilopoulos G, Zhang HC. Triple Threat: The Importance of Diagnosing "Triple-Negative" Primary Biliary Cholangitis. Dig Dis Sci 70(11):3653-3657, 2025. e-Pub 2025. PMID: 40555922.
- Shatila M, Devalaraju S, Takigawa K, Catinis C, Lee I, Baerman E, Ngo S, Mittal N, Glombicki S, Machado AP, Lu L, Aleem AS, Thompson J, Funchain P, Grover S, Zhang HC, Thomas AS, Wang Y. Worse Survival and Gastrointestinal Toxicity Outcomes Among Patients Receiving Proton Pump Inhibitors During Checkpoint Inhibitor Therapy. J Natl Compr Canc Netw 23(7):1-7, 2025. e-Pub 2025. PMID: 40533069.
- Shatila M, Machado AP, Shah J, Rivera AU, Naz S, Glombicki S, Wali S, Lu E, Short N, Thomas A, Zhang HC, Wang Y. Checkpoint Inhibition Prior to Stem Cell Transplantation Increases the Risk of Inflammatory Adverse Events. Target Oncol 20(2):329-337, 2025. e-Pub 2025. PMID: 39904838.
- Shah J, Caleb Urias Rivera A, Lee IJ, Takigawa K, Mathew A, Wu D, Lu E, Shatila M, Thomas AS, Zhang HC, Altan M, Zhao D, Xiao Q, Wang Y. The Effect of PD-1/PD-L1 Inhibitor and Statin Combination Therapy on Overall Survival and Gastrointestinal Toxicity. Am J Clin Oncol 48(3):136-141, 2024. e-Pub 2024. PMID: 39473073.
- Shaikh AS, Abraham SC, Wang LS, Torres HA, Zhang HC. Viral Hepatitis B Reactivation With Delayed Cholestatic Effect Secondary to Acalabrutinib. ACG Case Rep J 11(6):e01387, 2024. e-Pub 2024. PMID: 38903451.
- Raju, GS, Patel, K, Suresh, S, Zhang, HC, Diehl, A, Romero, L, Mahometano, LD, Reyes, S, Benitez-Romero, M, Slocum, T, Soetikno, R, Verdeyen, JM, Rach, JM, Dellert, EL, Villegas, R, Bruton, M, Gricar, J, Nicotera, P. Development of an endoscopy technician training certificate program in a community college. iGIE 3(2):153-162, 2024. e-Pub 2024. PMID: 41647074.
- Shatila, M, Eshaghi, F, Thomas, A, Kuang, AG, Shah, JS, Zhao, B, Naz, S, Sun, M, Fayle, S, Jin, J, Abudayyeh, A, Sheshadri, A, Palaskas, NL, Franco Vega, M, Gaeta, MS, Thomas, AS, Zhang, HC, Wang, Y. Practice Changes in Checkpoint Inhibitor-Induced Immune-Related Adverse Event Management at a Tertiary Care Center. Cancers 16(2), 2024. e-Pub 2024. PMID: 38254858.
- Sperling, G, Shatila, M, Varatharajalu, K, Lu, Y, Altan, M, Zhou, Y, Zhao, D, De Toni, EN, Török, HP, Schneider, BJ, Khan, A, Thomas, AS, Zhang, HC, Shafi, MA, Wang, Y. Pneumatosis intestinalis in cancer patients who received immune checkpoint inhibitors. Journal of Cancer Research and Clinical Oncology 149(19):17597-17605, 2023. e-Pub 2023. PMID: 37917197.
- Yibirin M, Mustafayev K, Hosry J, Pundhir P, Klingen J, Yepez Guevara E, Granwehr BP, Kaseb A, Naing A, Patel S, Shah AY, Skoulidis F, Tawbi H, Wang LS, Miller D, Zhang HC, Zurita-Saavedra A, Torres H. Immune Checkpoint Inhibitors Suppress Hepatitis C Virus Replication in Infected Patients With Solid Tumors. Am J Gastroenterol 118(9):1609 - 1617, 2023. e-Pub 2023. PMID: 37307533.
- Kuang AG, Sperling G, Liang TZ, Lu Y, Tan D, Bollin K, Johnson DB, Manzano JM, Shatila M, Thomas AS, Thompson JA, Zhang HC, Wang Y. Sclerosing mesenteritis following immune checkpoint inhibitor therapy. J Cancer Res Clin Oncol 149(11):9221 - 9227, 2023. e-Pub 2023. PMID: 37195298.
- Pizuorno Machado A, Shatila M, Liu C, Lu Y, Altan M, Glitza Oliva IC, Zhao D, Zhang HC, Thomas A, Wang Y. Characteristics, treatment, and outcome of patients with bowel perforation after immune checkpoint inhibitor exposure. J Cancer Res Clin Oncol 149(9):5989 - 5998, 2023. e-Pub 2023. PMID: 36611109.
- Pizuorno Machado A, Shatila M, Glitza Oliva IC, Altan M, Siddiqui B, Yan Z, Varatharajalu K, Zhang HC, Thomas A, Wang Y. Impact of Selective Immunosuppressive Therapy on Subsequent Immune-Related Adverse Events After Immune Checkpoint Inhibitor-Induced Colitis Treatment. Am J Clin Oncol 46(8):360 - 365, 2023. e-Pub 2023. PMID: 37219360.
- Nardo, M, Yilmaz, B, Nelson, BE, Torres HA, Wang LS, BPalma G, Song J, Dalla Pria HRF, Trinh VA, Glitza Oliva IC, Patel SP, Tannir NM, AOmar K, Altan M, Lee SS, Miller E, Zhang HC, Stephen BA, Naing A. Safety and Efficacy of Immune Checkpoint Inhibitors in Patients with Cancer and Viral Hepatitis: The MD Anderson Cancer Center Experience. Oncologist 28(8):714 - 721, 2023. e-Pub 2023. PMID: 36952233.
- Pizuorno Machado A, Shatila M, Liu C, Wang J, Altan M, Zhang HC, Thomas A, Wang Y. Immune-related adverse events after immune checkpoint inhibitor exposure in adult cancer patients with pre-existing autoimmune diseases. J Cancer Res Clin Oncol 149(9):6341 - 6350, 2023. e-Pub 2023. PMID: 36752908.
- Mathew A, Shatila M, Lai Z, Tan D, Oliva ICG, Wang J, Alhalabi O, Zhang HC, Thomas A, Wang Y. Characteristics of appendicitis after immune checkpoint inhibitor therapy among cancer patients. J Cancer Res Clin Oncol 149(8):4591-4599, 2023. e-Pub 2023. PMID: 36163559.
- Thomas A, Eyada M, Kono M, Varatharajalu K, Yang L, Xu G, Panneerselvam K, Shatila M, Altan M, Wang J, Thompson JA, Zhang HC, Khan MA, Raju GS, Thomas AS, Wang Y. Characteristics, treatment, and outcome of diverticulitis after immune checkpoint inhibitor treatment in patients with malignancies. J Cancer Res Clin Oncol 149(8):4805 - 4816, 2023. e-Pub 2023. PMID: 36242603.
- Liu C, Shatil M, Mathew A, Machado, Pizuomo Machado A, Thomas A, |Zhang HC, Thomas AS, Faleck D, Funchain P, Philpott J, Grivas P, Obeid M. Role of C-Reactive Protein in Predicting the Severity and Response of Immune-Mediated Diarrhea and Colitis in Patients with Cancer. J Cancer 14(10):1913 - 1919, 2023. e-Pub 2023. PMID: 37476185.
- Machado, AP, Shatila, M, De Toni, EN, Török, HP, Philpott, J, Zhao, D, Zhou, Y, Varatharajalu, K, Shafi, MA, Zhang, HC, Thomas, AS, Wang, Y. Colon Adenoma After Diagnosis of Immune Checkpoint Inhibitor–mediated Colitis. Journal of Cancer 14(14):2686-2693, 2023. e-Pub 2023. PMID: 37779873.
- Chiu CY, Zhang HC, Westin J, Hosing C, Torres HA. Hepatitis E Virus Infection in Cancer Patients. Transplant Cell Ther 28(11):788.e1-788.e5, 2022. e-Pub 2022. PMID: 36031077.
- Kuang AG, Mohajir W, Panneerselvam K, McQuade JL, Glitz Oliva IC, Khan MA, Zhang HC, Thomas AS, Wang Y. Diarrhea and colitis related to immune checkpoint inhibitor and BRAF/MEK inhibitor therapy. Ann Gastroenterol 36(1):45 - 53, 2022. e-Pub 2022. PMID: 36593813.
- Dutra BES, Wei D, Tan D, Alasadi M, Zhang HC, Thomas A, Thomas AS, Richards DM, Wang Y. Clinical Characteristics and Outcomes of Patients with Positive Celiac Serology and Cancer Therapy Exposure. J Cancer 13(3):815-822, 2022. e-Pub 2022. PMID: 35154450.
- Zhang, HC, Miller ED, Wang L. Tocilizumab as an Effective Steroid-Sparing Agent for the Treatment of Recurrent and Steroid-Dependent Immune Checkpoint Inhibitor-Mediated Hepatotoxicity: A Case Study and Insight into Pathophysiologyphysiology. Am J Gastroenterol 117(10S):1896 - e1897, 2022. e-Pub 2022.
- Ma W, Gong Z, Abu-Sbeih H, Peng Y, Peng F, Zou F, Charabaty A, Okhuysen PC, McQuade JL, Altan M, Zhang HC, Thomas AS, Wang Y. Outcomes of Immune Checkpoint Inhibitor-related Diarrhea or Colitis in Cancer Patients With Superimposed Gastrointestinal Infections. Am J Clin Oncol 44(8):402-408, 2021. e-Pub 2021. PMID: 34107499.
- Khurana S, Abu-Sbeih H, Ma W, Qiao W, Foo WC, Richards DM, Thomas AS, Khan A, Zhang HC, Wang Y. Clinical Characteristics and Outcomes of Eosinophilic Colitis in Patients With Cancer. Am J Clin Oncol 44(8):395-401, 2021. e-Pub 2021. PMID: 34091476.
- Panneerselvam K, Amin RN, Wei D, Tan D, Lum PJ, Zhang HC, Richards DM, Altan M, Grivas P, Thompson JA, Thomas AS, Wang Y. Clinicopathologic Features, Treatment Response, and Outcomes of Immune Checkpoint Inhibitor-Related Esophagitis. J Natl Compr Canc Netw 19(8):896-904, 2021. e-Pub 2021. PMID: 34102607.
- Eyada M, Taggart MW, Wang LS, Miller ED, Zhang HC. DIAGNOSIS AND CHARACTERISTICS OF IMMUNE CHECKPOINT INHIBITOR-MEDIATED CHOLANGIOPATHY: A CASE SERIES 160(6):S851-2, 2021. e-Pub 2021.
- Panneerselvam K, Szafron D, Amin R, Khurana S, Wei D, Tan D, Okhuysen P, Zhang HC, Thomas A, Wang Y. 241 Characteristics treatment and outcomes of cytomegalovirus infection in patients treated with immune checkpoint inhibitors 160:S51, 2021. e-Pub 2021.
- Ali H, Khurana S, Ma W, Peng Y, Jiang ZD, DuPont H, Zhang HC, Thomas AS, Okhuysen P, Wang Y. Safety and efficacy of fecal microbiota transplantation to treat and prevent recurrent Clostridioides difficile in cancer patients. J Cancer 12(21):6498-6506, 2021. e-Pub 2021. PMID: 34659541.
- Zou F, Wang X, Glitza Oliva IC, McQuade JL, Wang J, Zhang HC, Thompson JA, Thomas AS, Wang Y. Fecal calprotectin concentration to assess endoscopic and histologic remission in patients with cancer with immune-mediated diarrhea and colitis. J Immunother Cancer 9(1), 2021. e-Pub 2021. PMID: 33436487.
- Zhang HC, Taggart M, Miller ED, Fossella F, Wang L. Extrahepatic Biliary Sequelae in Immune Checkpoint Inhibitor-Mediated Cholangiohepatitis: Urgent Unmet Need for Early Effective Treatment. Am J Gastroenterol(116):S1139, 2021. e-Pub 2021.
- Zhang HC, Wang L, Wang Y, Miller ED. Budesonide as an Alternative Steroid Agent, in Combination With Adjunctive Agents, for the Treatment of Immune Checkpoint Inhibitor-Mediated Cholangiohepatitis: A Case Study. Am J Gastroenterol(116):S1139, 2021. e-Pub 2021.
- Zhang HC, Eyada M, Taggart M, Miller E, Negrao M, Varghese S, Wang L. Clinical Presentation, Treatment Strategies, and Chronic Sequelae of Immune Checkpoint Inhibitor-Mediated Cholangiopathy: A Case Study. Am J Gastroenterol(116):S1140, 2021. e-Pub 2021.
- Zou F, Abu-Sbeih H, Ma W, Peng Y, Qiao W, Wang J, Shah AY, Glitza Oliva IC, Piha-Paul SA, Thompson JA, Zhang HC, Thomas AS, Wang Y. Association of Chronic Immune-Mediated Diarrhea and Colitis With Favorable Cancer Response. J Natl Compr Canc Netw 19(6):700-708, 2020. e-Pub 2020. PMID: 33316767.
- Zhang HC, Luo W, Wang Y. Acute liver injury in the context of immune checkpoint inhibitor-related colitis treated with infliximab. J Immunother Cancer 7(1):47, 2019. e-Pub 2019. PMID: 30777137.
- Zhang HC, Dedania B, Thosani N. Management of choledocholithiasis by direct cholangioscopy via freehand intubationusing the "J" maneuver. VideoGIE 4(5):214-216, 2019. e-Pub 2019. PMID: 31061942.
- Cherian ET, Zhang HC, Guttenberg KB, Everett JM, Guha S. Looking beyond the Obvious: Eosinophilic Enterocolitis. Am J Med 131(6):e227-e229, 2018. e-Pub 2018. PMID: 29526542.
- Bond MR, Zhang H, Kim J, Yu SH, Yang F, Patrie SM, Kohler JJ. Metabolism of diazirine-modified N-acetylmannosamine analogues to photo-cross-linking sialosides. Bioconjug Chem 22(9):1811-1823, 2011. e-Pub 2011. PMID: 21838313.
- Bond MR, Zhang H, Vu PD, Kohler JJ. Photocrosslinking of glycoconjugates using metabolically incorporated diazirine-containing sugars. Nat Protoc 4(7):1044-1063, 2009. e-Pub 2009. PMID: 19536272.
Review Articles
- Rong J, Jafri F, Ngo S, Chatterjee A, Moura Nascimento Santos MJ, Garza D, Salim H, Menon R, Mortan R, Urias Rivera AC, Zhang HC, Patel A, Rojas Hernandez C, Jeff Li Y, Sheshadri A, Aaroe A, Shariff A, Schneider B, Thomas A, Wang Y. Rare irAEs associated with immune checkpoint inhibitor therapy. Expert Opin Drug Saf:1-15, 2026. e-Pub 2026. PMID: 41664562.
- Zhang HC, Tamil M, Kukreja K, Singhal S. Review of Simultaneous Double Stenting Using Endoscopic Ultrasound-Guided Biliary Drainage Techniques in Combined Gastric Outlet and Biliary Obstructions. Clin Endosc 53(2):167-175, 2020. e-Pub 2020. PMID: 31405265.
Professional Educational Materials
- Zhang HC. Nephrology Consults Teaching Guide for the BCM internal medicine residency program (first and second editions) Unofficial guide reviewed by Dr. José Perez, 2015.
Abstracts
- Soetikno R, Barsuk J, Maulahela H, Asokkumar R, Nguyen-Vu T, Deshpande AR, Cohen E, Zhang HC, Shane M, Skeans JM, Keswani RN, Patel RV, Kathpalia P, Pfeil S, Issenberg B, McGaghie W, Kaltenbach TR. SIMULATION-BASED MASTERY LEARNING BOOTCAMP ACCELERATES BASIC UPPER ENDOSCOPY SKILL ACQUISITION: A MULTICENTER STUDY OF GASTROENTEROLOGY FELLOWS. Digestive Disease Week (DDW) 2026, 2026. e-Pub 2026.
- Machado AP, Caskey KN, Shaikh AS, Wang L, Miller E, Wang Y, Zhang HC. Oral Budesonide for the Treatment of Immune Checkpoint Inhibitor-Mediated Hepatobiliary Toxicities: A Case Series. Digestive Disease Week (DDW) 2025, 2025. e-Pub 2025.
- Muftah AA, Waters R, Wang L, Zhang HC. Vanishing Bile Duct Syndrome in the Setting of Newly Diagnosed Hodgkin Lymphoma. Am J Gastroenterol 117(10S):e1992-e1993, 2022. e-Pub 2022.
- Machado AP, Shatila M, Liu C, Zhang HC, Thomas AS, Wang Y. Characteristics, Treatment and Outcome of Patients with Previously Diagnosed Autoimmune Disease After Immune Checkpoint Inhibitor Exposure. Am J Gastroenterol, 2022. e-Pub 2022.
- Chopra M, Waters R, Wang L, Zhang HC. Statin-Related Autoimmune Hepatitis: A Case Study of a Rare Entity and Review of Current Knowledge. Am J Gastroenterol, 2022. e-Pub 2022.
- Zhang HC, Miller ED, Wang L. Early Use of Tocilizumab as an Effective Steroid-Sparing Strategy for the Treatment of Immune Checkpoint Inhibitor-Mediated Cholangiopathy: Building Foundations for Personalized Management. Am J Gastroenterol 117(10S):1931, 2022. e-Pub 2022.
- Jacob JS, Dutra BE, Garcia-Rodriguez V, Panneerselvam K, Abraham FO, Zou F, Ma W, Grivas P, Thompson JA, Altan M, Oliva ICG, Zhang HC, Thomas AS, Wang Y. Clinical Characteristics and Outcomes of Oral Mucositis Associated With Immune Checkpoint Inhibitors in Patients With Cancer. J Natl Compr Canc Netw 19(12):1415-1424, 2021. e-Pub 2021. PMID: 34348238.
- Eyada M, Taggart MW, Wang LS, Miller ED, Zhang HC. Diagnosis and characteristics of immune checkpoint inhibitor-mediated cholangiopathy: A case series. Digestive Disease Week (DDW) 2021 160(6):S851-2, 2021. e-Pub 2021.
- Muftah A, Wang L, Zhang HC. Severe Cholestasis as a Paraneoplastic Phenomenon Associated With Adrenocortical Carcinoma, 2021. e-Pub 2021.
- Zhang HC, Eyada M, Miller E, Wang L. Tocilizumab as an alternative treatment strategy for immunotherapy-mediated hepatobiliary toxicity: addressing an urgent unmet need, 2021. e-Pub 2021.
- Zhang HC, Eyada M, Miller E, Wang L. TOCILIZUMAB AS AN ALTERNATIVE TREATMENT STRATEGY FOR IMMUNOTHERAPY-MEDIATED HEPATOBILIARY TOXICITY: ADDRESSING AN URGENT UNMET NEED. American Association for the Study of Liver Diseases (AASLD) 2021 - The Liver Meeting - Virtual 74(1(Suppl)), 2021. e-Pub 2021.
- Zhang HC, Taggart M, Miller ED, Fossella F, Wang L. Extrahepatic Biliary Sequelae in Immune Checkpoint Inhibitor-Mediated Cholangiohepatitis: Urgent Unmet Need for Early Effective Treatment 116:S1139, 2021. e-Pub 2021.
- Zhang HC, Wang L, Wang Y, Miller ED. Budesonide as an Alternative Steroid Agent, in Combination With Adjunctive Agents, for the Treatment of Immune Checkpoint Inhibitor-Mediated Cholangiohepatitis: A Case Study 116:S1139, 2021. e-Pub 2021.
- Zhang HC, Eyada M, Taggart M, Miller E, Negrao M, Varghese S, Wang L. Clinical Presentation, Treatment Strategies, and Chronic Sequelae of Immune Checkpoint Inhibitor-Mediated Cholangiopathy: A Case Study 116:S1140, 2021. e-Pub 2021.
- Khurana S, Abu-Sbeih H, Ma W, Foo WC, Zhang HC, Wang Y. Eosinophilic colitis in cancer patients. Journal of Clinical Oncology, 2020. e-Pub 2020.
Book Chapters
- Zhang HC, Shah J, Rashid A, Miller E, Msaouel P, Wang L. Immune Checkpoint Inhibitor-Mediated Hepatotoxicity: Personalized Management Based on Evolving Biochemical Behaviors. In: Challenging Cases in Immunotherapy Related Organ Toxicities. Springer, Cham, 2025.
- Zhang HC, Rivera AU, Miller E, Chun YS, Ledet CR, Wang L. Cholangiohepatitis with Extrahepatic Cholangiopathy and Cholecystitis Secondary to Immune Checkpoint Inhibitor Therapy. In: Challenging Cases in Immunotherapy Related Organ Toxicities. Springer, Cham, 257-265, 2025.
- Zhang HC, Ngo S, Chatterjee D, Miller E, Zurita AJ, Wang L. Hepatobiliary Toxicity Secondary to Immune Checkpoint Inhibitor Therapy: Early Tocilizumab Treatment to Decouple Steroid Dependency. In: Challenging Cases in Immunotherapy Related Organ Toxicities. Springer, Cham, 243-255, 2025.
- Zhang, HC, Miller, E, Wang, L, Rivera, AU, Chun, YS, Ledet, CR. Cholangiohepatitis with Extrahepatic Cholangiopathy and Cholecystitis Secondary to Immune Checkpoint Inhibitor Therapy, 257-265, 2025.
- Zhang, HC, Miller, E, Wang, L, Shah, JS, Rashid, A, Msaouel, P. Immune Checkpoint Inhibitor-Mediated Hepatotoxicity, 267-276, 2025.
- Zhang, HC, Miller, E, Wang, L, Ngo, S, Chatterjee, D, Zurita-Saavedra, A. Hepatobiliary Toxicity Secondary to Immune Checkpoint Inhibitor Therapy, 243-255, 2025.
- Bresalier RS, Coronel ES, Zhang HC. Gastrointestinal and Hepatic Complications in Cancer Patients. In: Holland-Frei Cancer Medicine. 10. Wiley-Blackwell, 2023.
- Zhang HC, Wang LS, Miller E. Hepatology (Liver and Bile Duct). In: Managing Immunotherapy Related Organ Toxicities: A Practical Guide. 1st Edition. Springer International Publishing, 119 - 165, 2022.
- Thomas AS, Zhang HC, Wang Y, Chari ST. Pancreas and Gallbladder. In: Managing Immunotherapy Related Organ Toxicities. A Practical Guide. Springer International, 255 - 264, 2022.
- Lee SS, Zhang HC, Tran Cao HS, Kuban JD, Koay EJ, Avritscher R, Kaseb AO. Hepatocellular Carcinoma. In: The MD Anderson Manual of Medical Oncology (4th Edition). 4. McGraw Hill, LLC, 2022.
- Zhang HC, Wang LS, Miller E. Hepatobiliary and Pancreatic Adverse Events. In: Immunotherapy (Fourth Edition). Springer Nature Switzerland AG, 339-355, 2021.
Letters to the Editor
- Khurana S, Chi Zhang H, Peng Y, Lu Y, Wang Y. Severe fistulizing pancreatitis in a patient with Merkel cell carcinoma treated with avelumab. Eur J Gastroenterol Hepatol 32: 1266-1267, 2020.
Patient Reviews
CV information above last modified September 03, 2026